BIOAF
Bioasis Technologies Inc.

Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE, is the previous chief executive officer and managing director at Bionomics. Dr. Rathjen joined Bionomics in 2000 from Peptech Limited, where she was the general manager of business development and licensing. Under Dr. Rathjen's leadership, Bionomics has advanced treatments for several CNS disorders, such as anxiety, depression and Alzheimer's disease. The Company's technologies include ionX for ion channel drug discovery and MultiCore a diversity-orientated small molecule chemistry platform. Dr. Rathjen was a co-inventor of Peptech's TNF technology and leader of the company's successful defense of its key TNF patents against a legal challenge by BASF and Johnson & Johnson. Dr. Rathjen has significant experience in company building and financing, mergers and acquisitions, therapeutic product research and development, business development, licensing and commercialization Dr. Rathjen has been recognized both in Australia and internationally through awards and honors including the 2014 Woman Executive of the Year BioPharm Industry Awards. In 2015 Dr. Rathjen was named amongst the top 50 most influential business women in Australia by The Australian newspaper. Dr. Rathjen received her doctor of philosophy degree in immunology from Macquarie University in Sydney, Australia and her bachelor of science degree in immunology from Flinders University in Adelaide, Australia.

David M. Wurzer, C.P.A., currently serves as executive vice president and chief investment officer at Connecticut Innovations (CI) in Rocky Hill, Conn. Mr. Wurzer is responsible for managing the investment function at CI. He also is responsible for oversight of the Connecticut Bioscience Innovation Fund (CBIF) and the Regenerative Medicine Research Fund (RMRF). When Mr. Wurzer joined CI in 2009 as senior managing director of investments, including more than 10 years as executive vice president, treasurer and chief financial officer of CuraGen Corporation, a former CI portfolio company. Mr. Wurzer began his professional career with Coopers & Lybrand in Hartford, Conn. (now part of PricewaterhouseCoopers). Mr. Wurzer currently serves on the board of directors for Standard Diversified Opportunities, Inc. (NASDAQ:SDOI), Summit Therapeutics (NASDAQ:SMMT; LON:SUMM), ReNetX Therapeutics (f/k/a Axerion Therapeutics), Natural Polymer Devices, Thetis Pharmaceuticals. Mr. Wurzer previously served on the board of directors for DUSA Pharmaceuticals (NASDAQ:DUSA), Response Genetics (NASDAQ:RGDX), 454 Life Sciences Corporation, CyVek, EmmeE2MS, LegiTime, My Gene Counsel, NovaTract Surgical, Sematifi, SmartPay Solutions and ZetrOZ. Mr. Wurzer is a board financial expert for SEC purposes and Certified Public Accountant. Mr. Wurzer earned his bachelor of business administration degree in accounting from the University of Notre Dame in Notre Dame, Ind.

Dave Jenkins has more than 35 years of experience in accounting and finance including 31 years at PwC, one of the world's largest accounting and consulting firms. At PwC, Jenkins was an audit partner, serving multinational public companies, private equity portfolio companies, and venture backed growth companies. He served companies in multiple sectors including bioscience, software, and healthcare. He has deep experience assisting companies raise capital, develop teams, evaluate and complete acquisitions, design well controlled systems, and expand internationally. Jenkins currently has his own advisory practice, Forest View Consulting, LLC, where he assists high growth technology and bioscience companies develop strategic business models, enhance business development, and evaluate key transactions. Jenkins earned his Bachelor of Arts degree in business administration and accounting from Muhlenberg College in Allentown, PA. where he also currently serves on the college's Board of Trustees.

Dr. Mei Mei Tian is a vice president and the head of external research at Bioasis Technologies, Inc. Dr. Tian has more than 10 years of experience working on melanotransferrin-related research in both academia and biotech. At the University of British Columbia, she investigated the role of melanotransferrin in melanoma malignancy, as well as mechanisms involved in melanotransferrin uptake in cells. Since joining the Bioasis team in 2012, she has been a significant contributor in the early development and continued expansion of our proprietary blood-brain barrier technology, xB3. With her oncology and neurology background, she is a committed and driven individual with a passion for the success of our platform. Dr. Tian received her doctor of philosophy degree in microbiology and immunology from the University of British Columbia.

Michael Partridge is a partner at Goodmans. His practice focuses on corporate finance, mergers and acquisitions, private equity transactions, venture capital financings and securities law. He advises boards of directors and activist shareholders on corporate governance matters and proxy contests. Partridge is recognized as a leading lawyer in the areas of mergers and acquisitions, corporate finance and securities, private equity and mining by The Canadian Legal Lexpert Directory, for corporate finance and securities by the Lexpert Guide to the Leading U.S./Canada Cross-border Corporate Lawyers in Canada, by the Lexpert Special Edition on Leading Canadian Lawyers in Global Mining, and for mergers and acquisitions and natural resources law by The Best Lawyers in Canada. Partridge joined Goodmans as an associate in 1998. From 2000 to 2002, Partridge was an associate at a Silicon Valley based law firm where his practice focused on the representation of emerging growth companies, publicly traded technology companies and venture capital funds in M&A transactions, venture capital financings and general corporate and securities law matters. He returned to Goodmans in 2003 and became a partner in 2005. He is a member of the Law Society of Upper Canada and the California State Bar. Partridge earned his bachelor of arts degree in history from the University of Western Ontario and his bachelor of laws degree from York University Osgoode Hall Law School.

Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE, is the previous chief executive officer and managing director at Bionomics. Dr. Rathjen joined Bionomics in 2000 from Peptech Limited, where she was the general manager of business development and licensing. Under Dr. Rathjen's leadership, Bionomics has advanced treatments for several CNS disorders, such as anxiety, depression and Alzheimer's disease. The Company's technologies include ionX for ion channel drug discovery and MultiCore a diversity-orientated small molecule chemistry platform. Dr. Rathjen was a co-inventor of Peptech's TNF technology and leader of the company's successful defense of its key TNF patents against a legal challenge by BASF and Johnson & Johnson. Dr. Rathjen has significant experience in company building and financing, mergers and acquisitions, therapeutic product research and development, business development, licensing and commercialization Dr. Rathjen has been recognized both in Australia and internationally through awards and honors including the 2014 Woman Executive of the Year BioPharm Industry Awards. In 2015 Dr. Rathjen was named amongst the top 50 most influential business women in Australia by The Australian newspaper. Dr. Rathjen received her doctor of philosophy degree in immunology from Macquarie University in Sydney, Australia and her bachelor of science degree in immunology from Flinders University in Adelaide, Australia.

John E. Curran, C.P.A., is a former partner with Deloitte & Touche LLP ("Deloitte"), most recently serving as office managing partner, the equivalent of business unit chief executive officer, of Deloitte's Hartford, Conn. practice and as a lead client service partner responsible for enterprise-wide solutions across all Deloitte's service lines (tax, audit, risk and consulting/technology). Mr. Curran became a partner in 1987 and retired in June 2018. Over the course of his career, Mr. Curran has served some of the firm's largest insurance clients as well as health care entities. He has been responsible for the client relationship, assembling and oversight of multifunctional teams, quality and risk, and financial performance. Mr. Curran's expertise includes mergers & acquisitions, financial reporting, corporate governance, SEC matters, regulatory, strategic business planning and initial public offerings (IPOs). Mr. Curran has also led numerous due diligence projects in the insurance industry for large private equity entities. Mr. Curran currently serves on the board of directors for the Richard M. Keane Foundation. He has previously served on the board of The Mark Twain House, The Greater Hartford Arts Council, The Boys & Girls Club of Harford and The Hartford Economic Insurance Cluster. Mr. Curran is a Certified Public Accountant and earned his bachelor of business administration degree in accounting from the University of Notre Dame in Notre Dame, Ind., United States.

Mario Saltarelli M.D. Ph.D. has more than 20 years of leadership experience in the biopharmaceutical sector, where he has focused on the identification, growth, and advancement of therapeutics development pipelines through the application of advanced translational paradigms. Dr. Saltarelli currently serves as Chief Medical Officer of Entrada Therapeutics in Boston. Previously, he served as Chief Medical Officer of Syntimmune, a mid-stage biopharmaceutical company focused on the development of therapeutics for rare autoimmune diseases, which was acquired by Alexion Pharmaceuticals in November 2018. Prior to Syntimmune, Dr. Saltarelli served as senior vice president and head of early development and neurology at Vertex Pharmaceuticals. Dr. Saltarelli earned his bachelor of science degree in psychology from the University of Illinois at Urbana-Champaign, a doctor of medicine degree and a doctor of philosophy degree in neuropharmacology from The Johns Hopkins University School of Medicine. He was an intern in internal medicine at the University of Maryland Medical Center and completed neurology residency at The Johns Hopkins Hospital.